Activity of a Novel 1,3-Beta-D-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata

被引：25
作者：
Ghannoum, M. [1 ,2 ]
Long, L. [1 ,2 ]
Isham, N. [1 ,2 ]
Hager, C. [1 ,2 ]
Wilson, R. [1 ,2 ]
Borroto-Esoda, K. [3 ]
Barat, S. [3 ]
Angulo, D. [3 ]
机构：
[1] Case Western Reserve Univ, Ctr Med Mycol, Cleveland, OH 44106 USA
[2] Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA
[3] Scynexis Inc, Jersey City, NJ USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 12期
关键词：
Candida glabrata; fks mutation; ibrexafungerp; MK-3118;
D O I：
10.1128/AAC.01510-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor with oral availability, was evaluated for activity against Candida glabrata. The susceptibility of clinical strains to ibrexafungerp was determined by microdilution and time-kill assays. The MIC range against wild-type strains was 1 to 2 mu g/ml. Ibrexafungerp was also active against the majority of echinocandin-resistant strains. Time-kill studies showed 4- to 6-log-unit reductions in growth at 24 and 48 h with concentrations of 0.25 to 4 mu g/ml.
引用
收藏
页数：3
相关论文
共 9 条
  • [1] Clinical Laboratory Standards Institute, 2012, M27S4 CLSI
  • [2] Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
    Garcia-Effron, Guillermo
    Chua, Daniel Joseph
    Tomada, Jon Rupert
    DiPersio, Joseph
    Perlin, David S.
    Ghannoum, Mahmoud
    Bonilla, Hector
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 2225 - 2227
  • [3] Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates
    Jimenez-Ortigosa, Cristina
    Paderu, Padmaja
    Motyl, Mary R.
    Perlin, David S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (02) : 1248 - 1251
  • [4] The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
    Judith Marcos-Zambrano, Laura
    Gomez-Perosanz, Marta
    Escribano, Pilar
    Bouza, Emilio
    Guinea, Jesus
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (07) : 1969 - 1976
  • [5] Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods
    Klepser, ME
    Ernst, EJ
    Lewis, RE
    Ernst, ME
    Pfaller, MA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) : 1207 - 1212
  • [6] Pfaller MA, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00161-17, 10.1128/aac.00161-17]
  • [7] Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)
    Pfaller, Michael A.
    Messer, Shawn A.
    Motyl, Mary R.
    Jones, Ronald N.
    Castanheira, Mariana
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (04) : 858 - 863
  • [8] Breakthrough Invasive Candidiasis in Patients on Micafungin
    Pfeiffer, Christopher D.
    Garcia-Effron, Guillermo
    Zaas, Aimee K.
    Perfect, John R.
    Perlin, David S.
    Alexander, Barbara D.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (07) : 2373 - 2380
  • [9] Schell WA, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01102-17, 10.1128/aac.01102-17]
1